Edition:
United States

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

5.54USD
22 Feb 2018
Change (% chg)

$-0.08 (-1.42%)
Prev Close
$5.62
Open
$5.43
Day's High
$5.66
Day's Low
$5.43
Volume
6,356
Avg. Vol
30,223
52-wk High
$15.19
52-wk Low
$4.84

Latest Key Developments (Source: Significant Developments)

Joseph Payne Reports 13.7 Pct Stake In Arcturus Therapeutics
Tuesday, 13 Feb 2018 11:48am EST 

Feb 13 (Reuters) - Arcturus Therapeutics Ltd ::JOSEPH PAYNE SAYS EMAILED LETTER DATED FEBRUARY 12, REQUESTED BOARD OF ARCTURUS THERAPEUTICS CONVENE EXTRAORDINARY GENERAL MEETING AS SOON AS POSSIBLE.JOSEPH PAYNE REPORTS 13.7 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF FEBRUARY 12 - SEC FILING.  Full Article

Certain Arcturus Therapeutics Shareholders Expressed Support For Former CEO Joseph Payne's Leadership
Tuesday, 6 Feb 2018 05:16pm EST 

Feb 6 (Reuters) - Arcturus Therapeutics Ltd ::FORMER CEO JOSEPH PAYNE SAYS HE WAS APPROACHED BY CERTAIN ARCTURUS THERAPEUTICS SHAREHOLDERS, WHO EXPRESSED SUPPORT FOR HIS CONTINUED LEADERSHIP.FORMER CEO PAYNE SAYS INTENDS TO DISCUSS WITH SUPPORTING SHAREHOLDERS POTENTIAL CHANGES TO COMPOSITION OF ARCTURUS THERAPEUTICS BOARD, MANAGEMENT.FORMER CEO PAYNE SAYS INTENDS TO DISCUSS WITH SUPPORTING SHAREHOLDERS HIS IMMEDIATE REINSTATEMENT AS PRESIDENT AND CEO OF ARCTURUS THERAPEUTICS.FORMER CEO JOSEPH PAYNE REPORTS A 13.7 PERCENT STAKE IN ARCTURUS THERAPEUTICS AS OF NOVEMBER 16, 2017 - SEC FILING.FORMER CEO PAYNE - TO DISCUSS WITH SUPPORTING SHAREHOLDERS CHANGES INCLUDING ELECTION OF NEW DIRECTORS TO REPLACE ARCTURUS THERAPEUTICS' BOARD MEMBERS.  Full Article

Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS.DEVELOPMENT COSTS WILL BE SHARED BETWEEN COS,WITH PLANS TO CO-COMMERCIALIZE PRODUCTS IN FUTURE UNDER PROFIT SHARING ARRANGEMENT.  Full Article

Arcturus Therapeutics Ltd Says Raised About $67.8 Million In Equity Financing
Thursday, 4 Jan 2018 06:17am EST 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD SAYS RAISED ABOUT $67.8 MILLION IN EQUITY FINANCING .  Full Article

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article

ARCTURUS, SYNTHETIC GENOMICS ANNOUNCE ALLIANCE TO DEVELOP VACCINES, THERAPEUTICS
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Synthetic Genomics::ARCTURUS THERAPEUTICS AND SYNTHETIC GENOMICS ANNOUNCE STRATEGIC ALLIANCE TO DEVELOP NEXT-GENERATION VACCINES AND THERAPEUTICS.UNDER COLLABORATION, CO WILL HAVE EXCLUSIVE ACCESS TO LUNAR TECHNOLOGY FOR VACCINES AND THERAPEUTICS, USING SELF-AMPLIFYING RNA​.UNDER, COLLABORATION, ‍ARCTURUS WILL RECEIVE UPFRONT CASH PAYMENT, RESEARCH AND DEVELOPMENT SUPPORT, PRE-CLINICAL, DEVELOPMENT, SALES MILESTONE PAYMENTS.‍UNDER COLLABORATION, ARCTURUS WILL ALSO RECEIVE ROYALTY PAYMENTS ON ANY FUTURE SUBLICENSED PRODUCTS ​.  Full Article

Alcobra Ltd Q2 loss per share $0.13
Friday, 11 Aug 2017 08:00am EDT 

Aug 11 (Reuters) - Alcobra Ltd :Alcobra announces second quarter 2017 financial results and provides corporate update.Qtrly loss per share $0.13.Announced that it had engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for process.Also exploring best path forward with its clinical assets, ADAIR and MDX ,including monetization and partnering.Company has also taken significant action to streamline its operations in order to preserve capital, including a 65% reduction in force.As part of recent reduction in force, Jonathan Rubin, co's chief medical officer, will be stepping down effective September 11, 2017.Appointed two new directors, Mr. Amir Efrati and Mr. Yuval Yanai, to Alcobra board of directors..  Full Article

Alcobra establishes special committee to explore, evaluate strategic alternatives
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Alcobra Ltd ::Alcobra updates on its review of strategic alternatives.Says ‍company also intends to streamline its operations in order to preserve its capital and cash resources​.Says ‍board has established a special committee to explore and evaluate strategic alternatives​.Alcobra - is continuing to assess best path forward for its abuse-deterrent amphetamine immediate-release (Adair), metadoxine extended release (MDX) clinical programs.Alcobra Ltd says ‍potential strategic alternatives that may be explored include potential for an acquisition, merger, business combination.Alcobra Ltd says ‍potential strategic alternatives that may be explored also include other strategic transaction involving company​.Says ‍engaged Ladenburg Thalmann & Co Inc to act as its strategic financial advisor for strategic alternatives​ process.  Full Article

Alcobra announces cooperation agreement with Brosh Group
Monday, 12 Jun 2017 08:36am EDT 

June 12 (Reuters) - Alcobra Ltd ::Alcobra announces cooperation agreement with Brosh Group and board additions.Alcobra Ltd says company to continue strategic alternatives process.Alcobra Ltd - appointed two new directors, Amir Efrati and Yuval Yanai, to Alcobra board of directors.Alcobra Ltd - as of 2 new appointments, alcobra board consists of ten directors.Alcobra Ltd - cooperation agreement also provides that co will continue its ongoing review of strategic alternatives.Company's upcoming AGM will be postponed until september 1, 2017.Alcobra Ltd - entered into a cooperation agreement with Brosh Capital Partners L.P. and certain of its affiliates.Alcobra ltd - under terms of agreement, Brosh Group is subject to certain customary standstill and other provisions.  Full Article

Alcobra reports Q1 loss per share $0.13
Tuesday, 30 May 2017 08:00am EDT 

May 30 (Reuters) - Alcobra Ltd :Alcobra announces first quarter 2017 financial results and provides corporate update.Alcobra Ltd qtrly loss per share $0.13.Alcobra Ltd says IND application for its amphetamine immediate release product candidate is expected to be filed with U.S. FDA in Q3 of this year.Alcobra Ltd says continues to evaluate strategic opportunities to expand its pipeline and enhance value for all its shareholders.  Full Article

BRIEF-Arcturus Therapeutics Comments On Amended 13D Filing

* ARCTURUS THERAPEUTICS LTD - COMMENTED ON AMENDED 13D FILING BY JOSEPH E. PAYNE